You are here

Cytokine Release Syndrome

Categories:

For those patients treated with dasatinib, I was sent a very interesting paper that was published in July 2019 - Please note that this research study was conducted on a mouse model. Even so, it is interesting in light of serious consequences (CRS) of a COVID-19 infection seen in some people.

"...The favorable pharmacodynamic attributes of dasatinib can be exploited to steer the activity of CAR T cells in "function-on-off-on" sequences in real time. In a mouse model of cytokine release syndrome (CRS), we demonstrated that a short treatment course of dasatinib, administered early after CAR T cell infusion, protects a proportion of mice from otherwise fatal CRS...."

....dasatinib acts as a pharmacologic on/off switch for CAR T cells
https://www.ncbi.nlm.nih.gov/pubmed/31270272

This is stunning -thanks Sandy!

Hi Scuba,

Yes, exciting for the future of CAR-T infusions used fo acute leukaemia etc. as CRS has been a real problem from the start. But if this pans out from the mice model and has the same effect in humans, then it will be a really important advance.

Sandy

This is an interview from a New York pulmonologist currently recovering from Covid-19 and his experience with a cytokine storm. If dasatinib does offer any protection from this should any of us be unlucky enough to contract this virus that would be fantastic, as his experience is very frightening.

https://www.salon.com/2020/04/05/what-it-feels-like-to-survive-covid-19s...